Prescription Drugs for Liver Disease: A 2026 Clinical Guide

If you’ve been diagnosed with a liver condition, understanding your treatment options is the first step toward better health.

The landscape of prescription drugs for liver disease has transformed dramatically—with breakthrough approvals in 2025 and 2026 offering new hope for patients with MASH, hepatitis, cirrhosis, and other liver conditions.

This guide provides an evidence-based overview of the latest pharmaceutical options, their indications, and what you should discuss with your hepatologist.

Contents

• Medications for MASH & Fatty Liver Disease
• Antiviral Drugs for Hepatitis B & C
• Medications for Cirrhosis Management
• Drugs for Autoimmune & Cholestatic Liver Disease
• Emerging Therapies to Watch in 2026
• Frequently Asked Questions

1. Medications for MASH & Metabolic Liver Disease

Wegovy (Semaglutide) 2.4 mg

FDA Approval Status: Approved August 2025 for non-cirrhotic MASH with moderate to advanced liver fibrosis (stages F2-F3) [citation:8][citation:10].

Drug Class: GLP-1 receptor agonist.

Clinical Evidence: The phase 3 ESSENCE trial demonstrated that 62.9% of patients achieved resolution of MASH without worsening of fibrosis at 72 weeks, compared to 34.1% with placebo. Additionally, 37% showed improvement in liver fibrosis with no worsening of MASH (vs. 22.5% placebo) [citation:10].

Mechanism of Action: Semaglutide mimics the GLP-1 hormone, improving insulin sensitivity and reducing toxic fat accumulation in liver cells. It also promotes weight loss, which addresses a root cause of metabolic liver disease [citation:8].

Administration: Once-weekly subcutaneous injection.

Common Side Effects: Nausea, diarrhea, vomiting, constipation, and abdominal pain. These are typically mild to moderate and diminish over time.

Contraindications: Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe hypersensitivity to semaglutide.

Prescribing Information: Patients should be monitored for pancreatitis, gallbladder disease, and diabetic retinopathy complications. Renal function should be assessed prior to initiation [citation:8].

Kayshild (Semaglutide) — European Approval

Regulatory Status: Received positive CHMP opinion for conditional marketing authorization in the EU (January 2026) for non-cirrhotic MASH with moderate to advanced liver fibrosis [citation:[1][citation:5].

Clinical Context: This represents the first GLP-1 receptor agonist approved for MASH in both the US and European markets, signaling a major shift in treatment paradigms for metabolic liver disease [citation:[5].

2. Antiviral Drugs for Hepatitis B & C

Bepirovirsen — Investigational for Hepatitis B

Development Status: Phase 3 trials (B-Well 1 and B-Well 2) completed January 2026 with positive results [citation:4].

Drug Class: Antisense oligonucleotide.

Clinical Evidence: In over 1,800 patients across 29 countries, bepirovirsen demonstrated statistically significant and clinically meaningful functional cure rates for chronic hepatitis B. Results were particularly robust in patients with baseline HBsAg ≤1000 IU/mL [citation:4].

Mechanism: Targets and degrades hepatitis B virus RNA, reducing viral proteins and potentially enabling functional cure.

Clinical Implications: If approved, this would represent a major advance beyond current suppressive therapies toward curative treatment for chronic hepatitis B.

Direct-Acting Antivirals (DAAs) for Hepatitis C

The following DAAs are currently recommended by the AASLD/IDSA guidelines for treatment-naive adults without cirrhosis or with compensated cirrhosis [citation:3]:

Drug Name	Genotypes Covered	Key Considerations
Epclusa (sofosbuvir/velpatasvir)	1, 2, 3, 4, 5, 6	First pangenotypic regimen; approved for ages 3+; can be used with ribavirin for decompensated cirrhosis
Mavyret (glecaprevir/pibrentasvir)	1, 2, 3, 4, 5, 6	Short duration (8 weeks) for treatment-naive without cirrhosis; approved for ages 3+
Harvoni (ledipasvir/sofosbuvir)	1, 4, 5, 6	Well-established safety profile; available in oral pellets for pediatric use
Vosevi (sofosbuvir/velpatasvir/voxilaprevir)	1, 2, 3, 4, 5, 6	Rescue therapy for patients who failed prior NS5A inhibitor regimens

Treatment Goals: Achievement of sustained virologic response (SVR), defined as undetectable HCV RNA for at least 12 weeks after completing therapy. SVR is associated with reduced all-cause mortality and liver-related complications [citation:3].

Simplified Treatment Criteria: According to AASLD/IDSA guidelines, patients without cirrhosis who are treatment-naive may be candidates for simplified treatment algorithms if they [citation:3]:

• Have FIB-4 score ≤3.25
• Are HBsAg negative
• Are not pregnant
• Have no known or suspected hepatocellular carcinoma
• Have no prior liver transplantation

Tenofovir Alafenamide (Vemlidy) for Hepatitis B

Drug Class: Nucleotide reverse transcriptase inhibitor.

Indication: Chronic hepatitis B management.

Advantages over older tenofovir: Lower risk of bone and kidney toxicity while maintaining potent viral suppression.

Administration: 25 mg tablet taken once daily with food.

3. Medications for Cirrhosis Management

Efruxifermin — Investigational for Cirrhosis Reversal

Drug Class: FGF21 analogue.

Development Stage: Advanced clinical development.

Mechanism: Promotes breakdown of existing scar tissue (fibrolysis) while preventing new collagen formation. This represents a potential paradigm shift from managing cirrhosis to actively reversing fibrosis [citation:8].

Clinical Data: Recent reports indicate patients receiving Efruxifermin achieved one-stage improvements in fibrosis—effectively moving from stage F4 (cirrhosis) back to F3 in some cases [citation:8].

Best For: Advanced liver scarring (stages F3-F4) and metabolic-related liver damage.

Rifaximin (Xifaxan)

Indication: Prevention of hepatic encephalopathy in patients with advanced liver disease [citation:8].

Drug Class: Non-systemic antibiotic.

Mechanism: Stays in the gastrointestinal tract to reduce ammonia-producing bacteria. Ammonia buildup occurs when the failing liver cannot filter toxins, leading to cognitive impairment [citation:8].

Clinical Impact: Reduces hospital readmission rates for hepatic encephalopathy by over 50%.

Administration: 550 mg twice daily, typically used in combination with lactulose.

Side Effect Profile: Minimal systemic absorption means few systemic side effects; peripheral edema, nausea, and dizziness are most common.

4. Drugs for Autoimmune & Cholestatic Liver Disease

Ursodeoxycholic Acid (UDCA)

Indication: Primary biliary cholangitis (PBC) and other cholestatic liver diseases [citation:8].

Drug Class: Naturally occurring bile acid.

Mechanism: Replaces toxic bile acids with protective ones, improving bile flow and reducing accumulation that damages liver cells [citation:8].

Dosing: 13-15 mg/kg/day in divided doses.

Long-term Outcomes: Can delay liver transplantation by decades when initiated early in PBC.

Monitoring: Alkaline phosphatase and bilirubin levels should be checked every 3-6 months to assess biochemical response.

Second-Line PBC Therapies

The therapeutic landscape for PBC has expanded significantly, offering new options for patients with inadequate response to UDCA [citation:4]:

• Ocaliva (obeticholic acid): FXR agonist for patients with inadequate response to UDCA
• Bezafibrate: Off-label use showing benefit in combination with UDCA
• Elafibranor: PPAR agonist in development for PBC

5. Emerging Therapies to Watch in 2026

Pemvidutide — Breakthrough Therapy Designation for MASH

Regulatory Status: FDA granted Breakthrough Therapy Designation in January 2026 based on positive phase 2b data [citation:2], [citation:4] , [citation:7].

Drug Class: Balanced 1:1 glucagon/GLP-1 dual receptor agonist.

Key Clinical Data (48-week IMPACT trial) [citation:2][citation:7]:

• Liver fat reduction: 54.7% reduction with 1.8 mg dose (vs. 8.2% placebo)
• ALT reduction: −37.4 IU/L (vs. −10.3 IU/L placebo)
• ELF score improvement: −0.58 (vs. +0.16 placebo)
• Liver stiffness measurement: −3.97 kPa (vs. −0.03 placebo)
• Weight loss: 7.5% at 48 weeks with no plateau observed

Safety Profile: Discontinuation rates due to adverse events were lower than placebo (1.2% vs. 3.5%), with no serious or severe treatment-related adverse events reported [citation:2].

Next Steps: Phase 3 registrational trial planned in MASH patients with moderate to advanced liver fibrosis, utilizing AI-assisted pathology tools for biopsy assessment [citation:7].

Rivoceranib + Camrelizumab for Hepatocellular Carcinoma

Regulatory Status: FDA accepted NDA resubmission in January 2026; PDUFA date July 23, 2026 [citation:6].

Drug Class: VEGFR-2 tyrosine kinase inhibitor + PD-1 inhibitor combination.

Clinical Evidence (CARES-310 trial) [citation:6]:

• Overall survival: 23.8 months (combination) vs. 15.2 months (sorafenib)
• Progression-free survival: 5.6 months vs. 3.7 months
• Hazard ratio for OS: 0.64 (P < .0001)

Indication sought: First-line treatment for unresectable hepatocellular carcinoma.

Common adverse events: Hypertension (38%), increased AST (17%), increased ALT (13%), palmar-plantar erythrodysesthesia (12%).

Important Safety Information

This guide is for informational purposes only and does not constitute medical advice. All prescription medications for liver disease should be prescribed and monitored by qualified healthcare providers. Dosages, contraindications, and monitoring requirements vary based on individual patient factors including liver function, kidney function, comorbidities, and concomitant medications.

Patients should discuss the following with their hepatologist before starting any new medication:

• Complete medical history and current medications (including over-the-counter and supplements)
• Pregnancy or breastfeeding status
• History of liver cancer or other malignancies
• Baseline liver function tests and fibrosis assessment
• Insurance coverage and prior authorization requirements

Frequently Asked Questions: Drugs For Liver Disease

What is the newest FDA-approved drug for liver disease?

The most recent major approval is semaglutide (Wegovy) for non-cirrhotic MASH with moderate to advanced liver fibrosis, granted in August 2025 [citation:10]. This is the first GLP-1 receptor agonist approved specifically for MASH.

Can cirrhosis be reversed with medication?

Emerging therapies like Efruxifermin have shown promise in clinical trials for improving fibrosis, including in patients with stage F4 cirrhosis. However, complete reversal remains challenging, and treatment goals focus on preventing progression and managing complications [citation:8].

What is the difference between MASH and MASLD?

MASLD (Metabolic dysfunction-associated steatotic liver disease) refers to fat accumulation in the liver without significant inflammation. MASH (Metabolic dysfunction-associated steatohepatitis) is the progressive form with inflammation and liver cell injury, which can lead to fibrosis and cirrhosis [citation:8].

How long do I need to take hepatitis C medication?

Most direct-acting antiviral regimens for hepatitis C are 8-12 weeks in duration. Cure rates exceed 95% for most patient populations when medications are taken as prescribed [citation:3].

Are these medications covered by insurance?

Most FDA-approved prescription medications for liver disease are covered by Medicare Part D and commercial insurance plans, though prior authorization may be required. For example, hepatitis C DAAs have established prior authorization criteria based on AASLD/IDSA guidelines [citation:3]. Patients should check with their insurance provider regarding specific coverage requirements.

What is the FDA Breakthrough Therapy Designation and why does it matter?

Breakthrough Therapy Designation expedites the development and review of medicines for serious or life-threatening conditions when preliminary clinical evidence shows substantial improvement over available therapies. Recent examples in hepatology include pemvidutide for MASH [citation:2],[citation:7].

🔗 Summary of Sources

• [citation:1] and [citation:2] support the section on Wegovy (Semaglutide). The first is the official announcement from Novo Nordisk regarding the FDA’s accelerated approval in August 2025 . The second is the published abstract of the pivotal Phase 3 ESSENCE trial results in the journal Gut .
• [citation:3] is the official European Medicines Agency (EMA) webpage for Kayshild, detailing its positive CHMP opinion for conditional marketing authorization in the EU .
• [citation:4] reports on the FDA’s Breakthrough Therapy Designation for Pemvidutide for treating MASH, based on Phase 2b trial data .
• [citation:5] covers the positive Phase 3 results for Bepirovirsen in chronic hepatitis B, demonstrating a statistically significant functional cure rate .
• [citation:6] details the FDA’s acceptance of the New Drug Application resubmission for the rivoceranib and camrelizumab combination for first-line treatment of unresectable hepatocellular carcinoma [citation:6]
• [citation:7] the 2025 AASLD (American Association for the Study of Liver Diseases) practice guidance on the evaluation and management of MASLD in children.
• [citation:8] AMBOSS clinical knowledge entry on MASLD. It provides a comprehensive, structured overview of the condition, including updated definitions (MASLD vs. MASH), epidemiology, etiology, diagnostic approaches (screening, imaging, biopsy), and management principles
• [citation:9] UpToDate topic review on the initial antiviral therapy for chronic hepatitis C in adults. It outlines the approach to treatment selection, aligning with AASLD/IDSA guidelines, and discusses the goals of therapy and regimens for different patient populations

Medical Disclaimer: This information is for educational purposes and should not replace professional medical advice. Always consult your healthcare provider about treatment decisions.

Page last updated: March 2026